Extended-spectrum beta-lactamase-producing Klebsiella spp. in a neonatal intensive care unit: risk factors for the infection and the dynamics of the molecular epidemiology
- 22 June 2007
- journal article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 26 (8) , 563-570
Abstract
The extended-spectrum beta-lactamase (ESBL)-producing Klebsiella spp. cause worldwide problems in intensive care units. The aim of this study was to investigate the molecular epidemiology of ESBL-producing Klebsiella pneumoniae and K. oxytoca strains in a neonatal intensive care unit (NICU) in Budapest, Hungary and to determine the risk factors of the infections and the epidemiological features. Infections with Klebsiella spp. were analyzed retrospectively by reviewing the medical records between January 2001 and December 2005. Antibiotic susceptibility tests, isoelectric focusing, pulsed field gel electrophoresis, plasmid analysis, PCR for bla TEM and bla SHV and DNA sequencing analysis were performed on ESBL-producing Klebsiella isolates. A total of 45 babies were found to be infected with non-ESBL-producing Klebsiella spp. and 39 with ESBL-producing Klebsiella spp. Of the parameters analyzed, including sex, gestational age, twin pregnancy, birth weight, presence of central vascular catheter, mechanical ventilator use, parenteral nutrition, polymicrobial infection, caesarean section, transfusion and mortality, we found no statistically significant difference between the ESBL and the non-ESBL groups, or between the K. pneumoniae and K. oxytoca species. Further characterization of the ESBL-producing K. pneumoniae and K. oxytoca strains isolated between February 2001 and January 2003 revealed three distinct PFGE patterns of SHV-5-producing K. pneumoniae (A, B, E) and two distinct patterns of SHV-12-producing K. oxytoca (C,D) isolates; these had different plasmid profiles. From July to November 2005, a new SHV-5 producing K. oxytoca (F) was isolated. The molecular epidemiology of ESBL-producing organisms in a NICU over time shows substantial shifts in predominant strains. The ESBL production of the infected organisms has an impact on the survival of newborn babies with infections caused by Klebsiella spp.Keywords
This publication has 44 references indexed in Scilit:
- Occurrence and regional distribution of SHV-type extended-spectrum β-lactamases in HungaryEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Frequency and diversity of Class A extended-spectrum β-lactamases in hospitals of the Auvergne, France: a 2 year prospective studyJournal of Antimicrobial Chemotherapy, 2004
- Involvement of SHV-12 and SHV-2a Encoding Plasmids in Outbreaks of Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae in a Tunisian Neonatal WardMicrobial Drug Resistance, 2004
- Extended-Spectrum β-Lactamases in Klebsiella pneumoniae Bloodstream Isolates from Seven Countries: Dominance and Widespread Prevalence of SHV- and CTX-M-Type β-LactamasesAntimicrobial Agents and Chemotherapy, 2003
- Extended-Spectrum β-Lactamase-ProducingKlebsiellapneumoniaein a Neonatal Intensive Care Unit in the High-Prevalence Area of Athens, GreeceJournal of Clinical Microbiology, 2002
- Multiresistant Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae Causing an Outbreak of Nosocomial Bloodstream InfectionInfection Control & Hospital Epidemiology, 2001
- Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance ThreatClinical Microbiology Reviews, 2001
- Outbreak of Infection with Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae in a Mexican HospitalJournal of Clinical Microbiology, 2001
- Extended-Spectrum TEM- and SHV-Type β-Lactamase-Producing Klebsiella pneumoniae Strains Causing Outbreaks in Intensive Care Units in ItalyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2000
- SHV-13, a Novel Extended-Spectrum β-Lactamase, in Klebsiella pneumoniae Isolates from Patients in an Intensive Care Unit in AmsterdamAntimicrobial Agents and Chemotherapy, 2000